Sodium salicylate augments the plasma adrenocorticotropin and cortisol responses to insulin hypoglycemia in man.
To test the hypothesis that prostaglandins attenuate neuroendocrine responses to changes in circulating glucose levels in man, we studied the effects of sodium salicylate (SS), a prostaglandin synthesis inhibitor, on the plasma ACTH and cortisol responses to insulin hypoglycemia. Six normal men were given insulin (0.05 U/kg, iv) on 2 different days during the infusion of either SS (40 mg/min) or saline. Compared to the saline control, SS had no significant effect on either the rate of fall of plasma glucose after insulin or the glucose nadir (mean +/- SEM, 33 +/- 3 vs. 36 +/- 3 mg/dl; P = NS). Peak ACTH levels after insulin were higher during SS compared to those during saline in all six subjects (316 +/- 95 vs. 102 +/- 26 pg/ml; P less than 0.05), and SS had a clear effect to increase both the overall ACTH response (F = 21.3; P less than 0.01, by analysis of variance) and the plasma cortisol response (F = 6.72; P less than 0.05, by analysis of variance). The most striking example of this effect of SS occurred in one subject whose peak plasma ACTH was only 44 pg/ml during saline but reached 750 pg/ml during SS despite an identical fall of plasma glucose to 42 mg/dl. Augmentation of the ACTH and cortisol responses to insulin hypoglycemia may be the result of an alteration by SS of recognition of glucose levels by glucose-sensitive cells of the brain, and effect which could be due to the inhibition of prostaglandin synthesis.
D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D007328:Insulin; D007700:Kinetics; D008297:Male; D011448:Prostaglandin Antagonists; D012980:Sodium Salicylate
D001786:Blood Glucose; D007328:Insulin; D011448:Prostaglandin Antagonists; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone; D012980:Sodium Salicylate